Plaintiffs further contend that Pfizer's sole purpose for traveling to Kano was to expedite the FDA's approval of Trovan to treat pediatric victims. (Compl. P 7.) Prior to Kano, only one child had ever been treated with Trovan, and then only after all other antibiotics failed. No child had ever received it orally. (Compl. P 105-06.) According to plaintiffs, Nigerian officials allocated to Pfizer two of IDH's wards to conduct the testing. (Compl. P 113.) Pfizer selected, from lines of those awaiting treatment, children ranging in age from one to thirteen years who exhibited symptoms of neck stiffness, joint stiffness, and high fevers with headaches. (Compl. P 3, 115.) Pfizer divided them into two groups and treated half with Trovan. (Compl. P 3.) The other half was "purposefully 'low-dosed'" with ceftriaxone, an FDA-approved drug shown to be effective in treating meningitis. (Compl. P 125.) In order to enhance the comparative results of Trovan, Pfizer administered only one-third of ceftriaxone's recommended dosage. (Compl. P 3, 124-25.)